header photo San Clemente 3/31/2021 6:30:00 AM
News / Business

Breakthrough on COVID-19 Vaccine Acknowledged by Global WholeHealth Partners, Corp. (OTC:GWHP) as AstraZeneca Aims to File Application With FDA While Dr. Anthony Fauci Says, "This is Very Likely a Very Good Vaccine”

Global WholeHealth Partners Corp (OTC:GWHP) offers one of the largest lines of tests for CoViD19 SARS2, and is prepared to help in the fight against CoViD19 SARS2. With the vaccine roll-out in progress, continued testing for COVID-19 is imperative and needs to remain a top priority to stop the spread of this deadly virus.

Breakthrough on COVID-19 Vaccine Acknowledged by Global WholeHealth Partners, Corp (OTC:GWHP) as AstraZeneca aims to file an application with the FDA while Dr. Anthony Fauci says, "This is very likely a very good vaccine."

Charles Strongo, CEO of Global WholeHealth Partners, Corp., said, "We were very encouraged by the AstraZeneca report that highlighted the effectiveness of their vaccine.” Strongo also mentioned that he agrees with Dr. Fauci, stating “the AstraZeneca vaccine is presumably very good” referring to an article that appeared in the New York Times and can be found here.

“We (Global) have been early supporters of the AstraZeneca vaccine and we’ve already secured the global distribution rights to sell this vaccine anywhere in the world,” Mr. Strongo affirmed.

A copy of the Global WholeHealth Partners, Corp 8K filing related to the distribution rights of the AstraZeneca vaccine can be found here.

“Hopefully AstraZeneca can get their application into the Food and Drug Administration as soon as possible so that we may see FDA authorization of the vaccine within the next 4 to 6 weeks,” Strongo expressed as he referred to an article from the Associated Press found here.

The AstraZeneca vaccine has been granted conditional marketing or emergency use authorization in more than 70 countries.

But it has yet to be approved in the United States, where President Joe Biden is stepping up the federal response to the pandemic by expanding testing, ramping up vaccinations and boosting production.

AstraZeneca forecast it would deliver 50 million doses to the United States within the first month of authorization and 15 to 20 million doses per month thereafter, drawing entirely on production sites in the country.

AstraZeneca reported Monday that its COVID-19 vaccine provided strong protection among adults of all ages in a long-anticipated U.S. study, a finding that could help rebuild public confidence in the shot around the world and move it a step closer to clearance in the U.S.

In the study of 30,000 people, the vaccine was 79% effective at preventing symptomatic cases of COVID-19 — including in older adults. There were no severe illnesses or hospitalizations among vaccinated volunteers, compared with five such cases in participants who received dummy shots — a small number, but consistent with findings from Britain and other countries that the vaccine protects against the worst of the disease.

“The CDC is still recommending that individuals who are already fully vaccinated for the COVID-19 virus should continue to get tested if they are experiencing any of the symptoms,” Charles Strongo reiterated.

CDC Recommendations for Fully Vaccinated People can be found here.

“There is no better way to Stop the Spread of COVID-19 and its various mutated strains then by utilizing the rapid antibody test kits that we offer to accurately detect those who have become infected and having them immediately quarantine,” says Charles Strongo, CEO of Global WholeHealth Partners, Corp.

Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.

With results in minutes versus hours or days with other diagnostic kits, the more lives that can be saved with the only FDA authorized COVID-19 POC serology Point of Care Test. With the new fingerstick test, healthcare providers can prick a patient’s finger and get results in minutes without having to wait for venous blood. Global WholeHealth Partners will be able to distribute these tests to more urgent cares, hospitals, and – to help curb the spread of CoViD19 SARS2.

Global WholeHealth Partners Corp. provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. It has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. The company was founded on March 7, 2013 and is headquartered in San Clemente, CA.

GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. Notably, GWHP offers a CE Mark for its high quality, rapid antibody test for COVID-19 and an EUA filing with the FDA is pending approval. In the interim, the US Navy in California has been using the test during 2Q20 and the Company has the capacity to deliver hundreds of thousands of tests, ramping up to 1 million per day. Currently, the Company has 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA.


The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

Media Contact:

Name: Charles Strongo,

CEO, Global WholeHealth Partners Corp.

Email: Sales@gwhpcorp.com


This press release contains "forward-looking statements.” Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.